ChinaAMC Hang Seng Hong Kong Biotech Index ETF
華夏恒生香港生物科技指數ETF

18 MAR 2021

China Asset Management (Hong Kong) Limited (“ChinaAMC (HK)”) is a wholly-owned subsidiary of China Asset Management Co. Limited that was incorporated in Hong Kong in September 2008. ChinaAMC (HK) is one of the first mainland Chinese fund management companies licensed to conduct asset management business in Hong Kong and one of the first RQFII fund managers. ChinaAMC (HK) is committed to developing offshore and cross-border asset management businesses in Hong Kong. Its vision is to become a pillar of the international financial architecture, helping to bridge the markets between China and the rest of the world. 

ChinaAMC (HK) has developed a broad range of product lines, including long-only funds, hedge funds, Exchange Traded Funds (ETFs), leveraged/Inverse products, bond funds, segregated accounts as well as investment advisory services in order to provide various products and services for both individual and institutional investors in Hong Kong, Greater China Region, Asia Pacific Region, Europe and the U.S. 

華夏基金（香港）有限公司（「華夏基金（香港）」）為華夏基金管理公司的全資子公司，於2008年9月在香港註冊成立，是首批獲准在港展開資管業務的中資基金公司，也是首批RQFII基金管理人。華夏基金（香港）致力在港發展離岸及跨境資產管理業務，願景成為中國與世界接軌的金融橋樑的中流砥柱之一。 

華夏基金（香港）建立了涵蓋長倉基金、對沖基金、交易所買賣基金(ETFs)、槓桿／反向產品、債券基金和專戶的多元化產品線，以及全力發展投資顧問服務，務求提供多類型產品或服務選擇予香港、大中華區、亞太區、以至歐洲、美國等地的個人及機構投資者。